City

Linyi (1)

Seoul (1)

Shenyang (1)

Suzhou (1)

Condition

Recruiting (4)

Completed (1)

T-cell Acute Lymphoblastic Leukemia (1)

Overall Status

Recruiting (3)

Completed (1)

Sign in for free

Phase

phase 3 (2)

phase 2 (1)

Sponsor

Samsung Medical Center (1)

Shandong New Time Pharmaceutical Co., LTD (1)

Shengjing Hospital (1)

The First Affiliated Hospital of Soochow University (1)

Collaborator

Affiliated Hospital of Nantong University (1)

First Affiliated Hospital Bengbu Medical College (1)

Jining Medical University (1)

Northern Jiangsu Province People's Hospital (1)

Suzhou Hospital of Traditional Chinese Medicine (1)

The Second People's Hospital of Huai'an (1)

Intervention

h02+chop (1)

rituxan +chop (1)

the effect of ligasure® to destroy cornual portion of fallopian tube (1)

venetoclax, azacitidine (1)

Study Documents

Intervention Type

drug (2)

device (1)

Funder Type

Other (3)

Industry (1)

Study Type

Interventional (3)

Observational (1)

recruiting

Showing 1 - 4 of 4

Trials per page:

STUDY

CONDITIONS

INTERVENTIONS

LOCATIONS

System Based on Big Data Analysis and Multimodule System

Recruiting

Recruiting

Shenyang, Liaoning, China

Shengjing Hospital of China Medical University

Jul 23, 2023

T-cell Acute Lymphoblastic Leukemia, Recruiting Trial in Suzhou (Venetoclax, Azacitidine)

Recruiting

T-cell Acute Lymphoblastic Leukemia
Recruiting

Venetoclax, Azacitidine

Suzhou, Jiangsu, China

The First Affliated Hospital of Soochow University

May 16, 2022

Recruiting Trial in Linyi (H02+CHOP, Rituxan +CHOP)

Recruiting

Recruiting

H02+CHOP
Rituxan +CHOP

Linyi, Shandong, China

Shandong New Time Pharmaceutical Co., LTD

Sep 7, 2021

Recruiting, Completed Trial in Seoul (The Effect of Ligasure® to Destroy Cornual Portion of Fallopian Tube)

Completed

Recruiting
Completed

The Effect of Ligasure® to Destroy Cornual Portion of Fallopian Tube

Seoul, Korea, Republic of

Samsung Medical Center

Apr 9, 2015